Los Angeles Capital Management’s Definium Therapeutics DFTX Stock Holding History

Los Angeles Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.7K	Buy	+618	New	+$10.5K	﹤0.01%	1907

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Los Angeles Capital Management's DFTX Position: Q1 2026 in Review

Los Angeles Capital Management opened a new position in Definium Therapeutics (DFTX) in Q1 2026: 618 shares worth $11.7K. The stake represents ﹤0.01% of the portfolio and ranks #1907 among its holdings.

247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

Los Angeles Capital Management held 618 shares of Definium Therapeutics worth $11.7K as of Q1 2026.
Definium Therapeutics was a new Los Angeles Capital Management position in Q1 2026.
Definium Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1907 holding.
247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.